SAV inhibited growth of 2 AML primagrafts. NRG mice bearing luc/YFP-labeled AML45 (A-C) and AML1526 (D-F) primagrafts were performed and data analyzed as in Figure 3. (A,D) BLI of each mouse at each time point in 1 experiment each with AML45 primagraft or AML1526 primagraft model, respectively. (B,E) Waterfall plots depict fold-change in luminescence on day 7 vs day 0 for each mouse, for primagraft experiments using AML45 and AML1526, respectively. (C,F) Kaplan-Meier survival plots for primagraft experiments using AML45 and AML1526, respectively. (C) Comparisons of vehicle vs ART838 plus VEN, vehicle vs ART838 plus SOR, vehicle vs VEN plus SOR, vehicle vs SAV, SAV vs ART838 plus VEN, SAV vs ART838 plus SOR, SAV vs VEN plus SOR all have P < .005. (F) Comparisons of vehicle vs ART838 plus VEN, vehicle vs ART838 plus SOR, vehicle vs VEN plus SOR, vehicle vs SAV, SAV vs ART838 plus VEN, SAV vs ART838 plus SOR, SAV vs VEN plus SOR all have P < .005, by log-rank (Mantel-Cox) test. (G) Aggregated results of 2 AML45 primagraft experiments and 1 AML1526 experiment are summarized. Inverse association between the fold-change (day 7/d 0) in AML burden and fold-change in median survival relative to vehicle for both AML45 and AML1526 were calculated using the Spearman rank correlation coefficient. nd, not done; “X”, mouse death.